Skip to Main Content

Author Details

Michael Fraser
Princess Margaret Cancer Centre, University Health Network
2001
64
37
PMIDPaper TitleJournal TitlePublished Year
32605887Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer.Eur Urol Oncol2022
35659150Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study.Eur Urol2022
36309516The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors.Nat Commun2022
36251389The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.Cancer Res2022
33357993Evidence for Focal Grade Group Progression in Low-risk Prostate Cancer.Eur Urol2021
33741908CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer.Nat Commun2021
34824250The telomere length landscape of prostate cancer.Nat Commun2021
34642184Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors.Cancer Res2021
34716314Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse.Nat Commun2021
34743445Dimensional reduction based on peak fitting of Raman micro spectroscopy data improves detection of prostate cancer in tissue specimens.J Biomed Opt2021
34167926Biorepositories and Databanks for the Development of Novel Biomarkers for Genitourinary Cancer Prevention and Management.Eur Urol Focus2021
33420488Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression.Nat Cell Biol2021
31161221Temporal Stability and Prognostic Biomarker Potential of the Prostate Cancer Urine miRNA Transcriptome.J Natl Cancer Inst2020
31932493Diverse <i>AR</i> Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer.Clin Cancer Res2020
31974375Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer.Nat Commun2020
32797086Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case-control study with multicohort validation.PLoS Med2020
30642810What Is Oligometastatic Prostate Cancer?Eur Urol Focus2019
31900906Prostate Cancer Genomic Subtypes.Adv Exp Med Biol2019
31735626Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors.Cancer Cell2019
30170099Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy.Int J Radiat Oncol Biol Phys2019
31591588Genome-wide germline correlates of the epigenetic landscape of prostate cancer.Nat Med2019
30808988The influence of BRCA2 mutation on localized prostate cancer.Nat Rev Urol2019
31010599Separating the Dreadful from the Merely Bad: Towards Prognostic and Predictive Biomarkers in Metastatic Castration-resistant Prostate Cancer.Eur Urol2019
30735634Widespread and Functional RNA Circularization in Localized Prostate Cancer.Cell2019
30889379The Proteogenomic Landscape of Curable Prostate Cancer.Cancer Cell2019
30643250Molecular landmarks of tumor hypoxia across cancer types.Nat Genet2019
29295717Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.BMC Cancer2018
30253747Valection: design optimization for validation and verification studies.BMC Bioinformatics2018
29662167Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.Nat Genet2018
29681457The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression.Cell2018
29275835A Partner in Crime: Tumor-associated Stroma and Metastatic Prostate Cancer.Eur Urol2018
28067867Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.Nat Commun2017
28376164Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer.J Natl Cancer Inst2017
28939825Mitochondrial mutations drive prostate cancer aggression.Nat Commun2017
28783165TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer.Nat Genet2017
28511883A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.Eur Urol2017
28605401Comparison of pre-processing methods for Infinium HumanMethylation450 BeadChip array.Bioinformatics2017
27815082Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors.Eur Urol2017
28068672Genomic hallmarks of localized, non-indolent prostate cancer.Nature2017
26885716Clonality of localized and metastatic prostate cancer.Curr Opin Urol2016
27526323Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer.Nat Genet2016
27516195BAMQL: a query language for extracting reads from BAM files.BMC Bioinformatics2016
24768356Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer.Urol Oncol2015
26018901Corrigendum: analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.Nat Genet2015
26005866Spatial genomic heterogeneity within localized, multifocal prostate cancer.Nat Genet2015
25730763Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.Nat Genet2015
24646301ShatterProof: operational detection and quantification of chromothripsis.BMC Bioinformatics2014
25456371Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study.Lancet Oncol2014
25539912WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma.Acta Neuropathol Commun2014
25173705SeqControl: process control for DNA sequencing.Nat Methods2014
  • 1 - 50 of 64

Recommended Authors

Wei Yuan
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 18
Joshua Armenia
Oncology R&D
Career Start Year 2013
Number of shared co-authors 18
Himisha Beltran
Dana-Farber Cancer Institute
Career Start Year 2010
Number of shared co-authors 80
Adam G Sowalsky
National Cancer Institute
Career Start Year 2010
Number of shared co-authors 17
Mohammed Alshalalfa
University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 48
Anne Haegert
University of British Columbia
Career Start Year 2008
Number of shared co-authors 24
Susana Miranda
The Institute of Cancer Research
Career Start Year 2008
Number of shared co-authors 18
Verena Sailer
Institute for Pathology, University Hospital Schleswig-Holstein
Career Start Year 2007
Number of shared co-authors 6
Robert J Lonigro
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 2007
Number of shared co-authors 15
Tamara L Lotan
Johns Hopkins University School of Medicine
Career Start Year 2006
Number of shared co-authors 47
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 8
Robert H Bell
University of British Columbia
Career Start Year 2004
Number of shared co-authors 25
Adam Sharp
The Institute for Cancer Research
Career Start Year 2003
Number of shared co-authors 20
Christopher E Barbieri
Weill Cornell Medical College
Career Start Year 2003
Number of shared co-authors 15
Scott A Tomlins
Rogel Cancer Center, University of Michigan Medical School ann arbor
Career Start Year 2003
Number of shared co-authors 57
Ladan Fazli
University of British Columbia
Career Start Year 2002
Number of shared co-authors 66
Wassim Abida
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 26
Heather H Cheng
Fred Hutchinson Cancer Center, University of Washington
Career Start Year 2002
Number of shared co-authors 31
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 9
Ilsa Coleman
Fred Hutchinson Cancer Center
Career Start Year 2001
Number of shared co-authors 39
Yuzhuo Wang
University of British Columbia
Career Start Year 2000
Number of shared co-authors 66
Xuhong Cao
Michigan Center for Translational Pathology.
Career Start Year 1999
Number of shared co-authors 23
Srinivasan Yegnasubramanian
Johns Hopkins University School of Medicine
Career Start Year 1999
Number of shared co-authors 16
Phillip G Febbo
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 41
Joaquin Mateo
Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital Campus
Career Start Year 1997
Number of shared co-authors 34
Arul M Chinnaiyan
University of Michigan Medical School.
Career Start Year 1993
Number of shared co-authors 81
Peter S Nelson
Fred Hutchinson Cancer Center
Career Start Year 1993
Number of shared co-authors 67
Rosina T Lis
National Cancer Institute
Career Start Year 1992
Number of shared co-authors 29
Gyorgy Petrovics
Henry Jackson Foundation for the Advancement of Military Medicine (HJF)
Career Start Year 1990
Number of shared co-authors 36
Mark A Rubin
University of Bern
Career Start Year 1990
Number of shared co-authors 90

Collaborators

Robert G Bristow
University of Toronto
Co-authored papers 43
Paul C Boutros
University of California los angeles
Co-authored papers 42
Theodorus H van der Kwast
University Health Network, University of Toronto
Co-authored papers 30
Julie Livingstone
University of California los angeles
Co-authored papers 13
Vincent Huang
Ontario Institute for Cancer Research
Co-authored papers 12
Yu-Jia Shiah
Ontario Institute for Cancer Research
Co-authored papers 11
Housheng Hansen He
Princess Margaret Cancer Center, University Health Network, University of Toronto
Co-authored papers 11
Takafumi N Yamaguchi
University of California los angeles
Co-authored papers 11
Alejandro Berlin
University of Toronto, Princess Margaret Cancer Centre
Co-authored papers 10
Melvin L K Chua
National Cancer Centre Singapore
Co-authored papers 10
Lawrence E Heisler
Ontario Institute for Cancer Research
Co-authored papers 9
Mathieu Lupien
Princess Margaret Cancer Research Centre
Co-authored papers 9
Emilie Lalonde
University of Pennsylvania
Co-authored papers 9
Bernard T??tu
Centre de Recherche du CHU de Quebec-Universite Laval (axe Oncologie)
Co-authored papers 9
John D McPherson
Ontario Institute for Cancer Research
Co-authored papers 8
Cindy Q Yao
Ontario Institute for Cancer Research
Co-authored papers 7
Mich??le Orain
Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Universite Laval
Co-authored papers 7
Musaddeque Ahmed
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 7
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 7
Alain Bergeron
Centre de recherche sur le cancer de l'Universite Laval
Co-authored papers 7
Neil E Fleshner
University of Toronto
Co-authored papers 7
Yves Fradet
CHU de Quebec-Universite Laval
Co-authored papers 7
Fouad Yousif
Ontario Institute for Cancer Research
Co-authored papers 7
H??l??ne Hovington
Centre de Recherche du CHU de Quebec-Universite Laval (axe Oncologie)
Co-authored papers 7
Shadrielle Melijah G Espiritu
Ontario Institute for Cancer Research
Co-authored papers 6
Rosalind A Eeles
The Institute of Cancer Research
Co-authored papers 6
Ken J Kron
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 6
Junjie T Hua
School of Public Health, Sun Yat-sen University
Co-authored papers 6
Alice Meng
Tufts University School of Medicine
Co-authored papers 6
David E Neal
University of Oxford, John Radcliffe Hospital
Co-authored papers 6
Release 1.2